Literature DB >> 19154728

Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.

Huub H van Rossum1, Fred P H T M Romijn, Nico P M Smit, Johan W de Fijter, Johannes van Pelt.   

Abstract

The calcineurin inhibitors cyclosporin A and tacrolimus and the inhibitors of the mTOR, sirolimus and everolimus bind immunophilins that are required for their immunosuppressive action. In contrast to cyclosporin A, tacrolimus and the mTOR inhibitors (MTIs) share common immunophilins, the FK506-binding proteins (FKBPs). We investigated the immunosuppressive interactions of MTIs on tacrolimus based immune suppression, since insights in immunological drug-drug interactions can be very relevant for optimization of immunosuppressive regimens in allograft transplantation medicine. Isolated peripheral blood mononuclear cells from healthy volunteers were incubated with combinations of MTIs and calcineurin inhibitors and when monitored for calcineurin activity and IL-2 excretion after mitogen stimulation, tacrolimus IC(50) concentrations shifted to higher concentrations in the presence of MTIs. This antagonism was absent for cyclosporin A, reproducible for 10 healthy volunteers (p<0.001) and stronger for sirolimus than for everolimus. When cell lysate was treated with and without MTI, tacrolimus and FKBP12, FKBP12 could increase calcineurin inhibition by tacrolimus and reverse the MTI antagonism for both MTIs. These results demonstrate that FKBP12 can be rate limiting for calcineurin inhibition at high tacrolimus concentrations and that the antagonism of sirolimus and everolimus on tacrolimus based immune suppression is mediated via saturation of FKBP12.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19154728     DOI: 10.1016/j.bcp.2008.12.009

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

Review 1.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

2.  mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.

Authors:  Christina L Avila; Jason M Zimmerer; Steven M Elzein; Thomas A Pham; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

Review 3.  Potential therapeutic effects of mTOR inhibition in atherosclerosis.

Authors:  Ammar Kurdi; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

4.  Adoptive Cell Transfer of Allogeneic Epstein-Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report.

Authors:  Bjoern-Thore Hansen; Petra Bacher; Britta Eiz-Vesper; Steffen M Heckl; Wolfram Klapper; Karoline Koch; Britta Maecker-Kolhoff; Claudia D Baldus; Lars Fransecky
Journal:  Front Immunol       Date:  2021-12-03       Impact factor: 7.561

5.  Tacrolimus ameliorates functional disturbances and oxidative stress in isoproterenol-induced myocardial infarction.

Authors:  Arash Khorrami; Mojtaba Hammami; Mehraveh Garjani; Nasrin Maleki-Dizaji; Alireza Garjani
Journal:  Daru       Date:  2014-10-14       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.